Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case

Active, not recruitingOBSERVATIONAL
Enrollment

1,500

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Sickle Cell Disease
Interventions
OTHER

Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result

"O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result.~O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care.~O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation.~O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs.~O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices."

Trial Locations (3)

Unknown

Azienda Ospedale Università Padova, Padua

UMC Utrecht, Utrecht

08035

Vall Hebron Institut de Recerca, Barcelona

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Universidad Politecnica de Madrid

OTHER

collaborator

Datawizard SRL

UNKNOWN

collaborator

University of Southampton

OTHER

collaborator

Humanitas Mirasole SpA

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

Universita degli Studi di Padova

UNKNOWN

collaborator

Assistance Publique - Hôpitaux de Paris

OTHER

collaborator

Vicomtech

UNKNOWN

collaborator

GLSMED Learning Health S.A.

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

Intrasoft

UNKNOWN

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER